Similar articles

• Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.

  Mullins CD, Ohsfeldt RL. Mullins CD, et al. J Manag Care Pharm. 2003 Mar-Apr;9(2):150-8. doi: 10.18553/jmcp.2003.9.2.150. J Manag Care Pharm. 2003. PMID: 14613344 Free PMC article.
• Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

  Reid IR. Reid IR. Expert Opin Drug Saf. 2002 May;1(1):93-107. doi: 10.1517/14740338.1.1.93. Expert Opin Drug Saf. 2002. PMID: 12904164 Review.
• Drug therapy for osteoporosis management in nursing home residents.

  Lee VK, McCarthy MW. Lee VK, et al. Lippincotts Prim Care Pract. 1999 Mar-Apr;3(2):150-62. Lippincotts Prim Care Pract. 1999. PMID: 10426058 Review. No abstract available.
• [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].

  Pfeilschifter J. Pfeilschifter J. Orthopade. 2001 Jul;30(7):462-72. doi: 10.1007/s001320170079. Orthopade. 2001. PMID: 11515185 Review. German.
• [Rational and cost effective osteoporosis prevention and therapy].

  Pfeilschifter J. Pfeilschifter J. Internist (Berl). 2002 Apr;43(4):554-62. doi: 10.1007/s001080100415. Internist (Berl). 2002. PMID: 12053412 German. No abstract available.